Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOMA J PORTER

Allopathic & Osteopathic Physicians Urology

NPI
1073560058
CMS profile
3114
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,114.96

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,114.96 54

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOMA J PORTER

NPI 1073560058 · CMS profile ID 3114

Allopathic & Osteopathic Physicians / Urology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073560058?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOMA J PORTER, NPI 1073560058, CMS profile ID 3114. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073560058?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HOMA J PORTER, NPI 1073560058, CMS profile ID 3114. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073560058?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HOMA J PORTER, NPI 1073560058, CMS profile ID 3114, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1073560058?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $1,114.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sumitomo Pharma America, Inc. $18.5812/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905307 CMS
Sumitomo Pharma America, Inc. $26.8312/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905305 CMS
PROCEPT BioRobotics Corporation $17.1112/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144035842 CMS
Endo USA, Inc. $24.2512/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138586400 CMS
Tolmar, Inc. $20.1711/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138704628 CMS
Verity Pharmaceuticals Inc. $12.0411/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602504 CMS
ABBVIE INC. $20.6810/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105296221 CMS
Sumitomo Pharma America, Inc. $29.0310/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905303 CMS
Merck Sharp & Dohme LLC $48.9910/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141601493 CMS
IMMUNITYBIO, INC. $13.7109/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125510112 CMS
Verity Pharmaceuticals Inc. $6.7609/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602483 CMS
Endo USA, Inc. $22.2309/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138586398 CMS
Novartis Pharmaceuticals Corporation $31.3009/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087310087 CMS
Dendreon Pharmaceuticals LLC $34.4009/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322371 CMS
Verity Pharmaceuticals Inc. $12.8409/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602499 CMS
Sumitomo Pharma America, Inc. $29.4709/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905301 CMS
Janssen Biotech, Inc. $33.0808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078704328 CMS
Sumitomo Pharma America, Inc. $29.3508/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905299 CMS
PROCEPT BioRobotics Corporation $14.5407/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144035840 CMS
PFIZER INC. $18.8807/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131795766 CMS
Verity Pharmaceuticals Inc. $9.0007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602487 CMS
Dendreon Pharmaceuticals LLC $34.4607/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322369 CMS
Merck Sharp & Dohme LLC $20.5706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141601495 CMS
Sumitomo Pharma America, Inc. $25.6806/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905297 CMS
Verity Pharmaceuticals Inc. $12.2906/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602520 CMS
COLOPLAST CORP $14.6406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117457126 CMS
Dendreon Pharmaceuticals LLC $34.2005/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322367 CMS
Verity Pharmaceuticals Inc. $12.0405/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602516 CMS
Merck Sharp & Dohme LLC $20.8205/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141839059 CMS
Verity Pharmaceuticals Inc. $7.1605/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602508 CMS
Sumitomo Pharma America, Inc. $28.4805/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905295 CMS
Dendreon Pharmaceuticals LLC $34.7404/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322365 CMS
Boston Scientific Corporation $14.2504/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092603942 CMS
Endo Pharmaceuticals Inc. $23.2004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137016840 CMS
Tempus AI, Inc $20.0104/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150172161 CMS
Verity Pharmaceuticals Inc. $8.4504/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602512 CMS
Verity Pharmaceuticals Inc. $12.8404/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602528 CMS
Mission Pharmacal Company $9.1803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1067522472 CMS
Dendreon Pharmaceuticals LLC $34.3103/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322363 CMS
Verity Pharmaceuticals Inc. $12.5603/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602532 CMS
Sumitomo Pharma America, Inc. $26.3803/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148905293 CMS
Olympus America Inc. $16.5203/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108472330 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.1302/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086203263 CMS
Verity Pharmaceuticals Inc. $11.1102/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602495 CMS
AstraZeneca Pharmaceuticals LP $19.4902/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104711457 CMS
Dendreon Pharmaceuticals LLC $30.6802/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149322361 CMS
Tolmar, Inc. $15.3902/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138704626 CMS
Olympus America Inc. $17.2402/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108472328 CMS
Verity Pharmaceuticals Inc. $10.8202/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080602491 CMS
Innovation Technologies Inc $23.5301/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130823226 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $497.35 30
PY2020 $85.54 5
PY2021 $396.93 21
PY2022 $689.93 32
PY2023 $872.15 41
PY2024 $1,114.96 54
PY2025 $2,382.91 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $503,343.98 37
PY2024 Principal investigator $739,851.51 38
PY2023 Principal investigator $476,035.66 7
PY2020 Principal investigator $20,519.40 6
PY2019 Recipient $735.51 6
PY2019 Principal investigator $58,065.60 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Urology Clinics of North Texas, PLLC
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926385
Principal investigator 1 Janssen Research & Development, LLC $12,218.00 12/29/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175409040
Principal investigator 1 Janssen Research & Development, LLC $29,802.00 12/29/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175409093
Principal investigator 1 Janssen Research & Development, LLC $18,008.00 12/29/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175409153
Principal investigator 1 Janssen Research & Development, LLC $1,024.00 12/15/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175409163
Principal investigator 1 Merck Sharp & Dohme LLC $18,598.70 12/01/2025 Non-covered Recipient Entity
Urology Clinics of North Texas, PLLC
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926383
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,538.00 11/25/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies No dispute reported 06/30/2026 1225415244
Principal investigator 1 Janssen Research & Development, LLC $15,232.00 11/07/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175409058
Principal investigator 1 Janssen Research & Development, LLC $6,176.00 11/03/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175409063
Principal investigator 1 Janssen Research & Development, LLC $7,104.00 10/23/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175409121
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,269.00 10/13/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies No dispute reported 06/30/2026 1225414094
Principal investigator 1 Janssen Research & Development, LLC $11,429.00 10/03/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175409109
Principal investigator 1 Janssen Research & Development, LLC $9,423.00 10/02/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175409136
Principal investigator 1 Janssen Research & Development, LLC $11,954.00 09/08/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409088
Principal investigator 1 Janssen Research & Development, LLC $6,208.00 09/08/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175409158
Principal investigator 1 Janssen Research & Development, LLC $15,736.00 08/11/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409105
Principal investigator 1 Astellas Pharma Global Development $464.00 07/31/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234187935
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,269.00 07/28/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies No dispute reported 06/30/2026 1225412916
Principal investigator 1 Janssen Research & Development, LLC $8,590.00 07/28/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175409046
Principal investigator 1 Janssen Research & Development, LLC $15,639.00 07/07/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175409051
Principal investigator 1 Janssen Research & Development, LLC $12,808.00 06/06/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175409077
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,538.00 06/02/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies No dispute reported 06/30/2026 1225412374
Principal investigator 1 Janssen Research & Development, LLC $18,141.00 06/02/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175409141
Principal investigator 1 Janssen Research & Development, LLC $3,035.00 05/19/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175409083
Principal investigator 1 Janssen Research & Development, LLC $24,066.00 05/12/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409032
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,900.00 04/30/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies No dispute reported 06/30/2026 1225402589
Principal investigator 1 Astellas Pharma Global Development $729.00 04/15/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234187933
Principal investigator 1 Janssen Research & Development, LLC $10,750.00 04/07/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175409071
Principal investigator 1 Janssen Research & Development, LLC $17,879.00 04/07/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409173
Principal investigator 1 Janssen Research & Development, LLC $11,552.00 03/27/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409132
Principal investigator 1 Astellas Pharma Global Development $1,193.00 03/19/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234187931
Principal investigator 1 Janssen Research & Development, LLC $72,792.00 03/10/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175409099
Principal investigator 1 Janssen Research & Development, LLC $31,027.00 03/10/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409126
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,269.00 02/25/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies No dispute reported 06/30/2026 1225402647
Principal investigator 1 Janssen Research & Development, LLC $41,822.00 02/03/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175409115
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,269.00 01/27/2025 Non-covered Recipient Entity
Urology Clinics Of North Texas
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies No dispute reported 06/30/2026 1225403161
Principal investigator 1 Janssen Research & Development, LLC $19,401.00 01/02/2025 Non-covered Recipient Entity
UROLOGY CLINICS OF NORTH TEXAS PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175409147